They’d Tried Everything Else. Then They Tried Cannabis.

A new JAMA study of first-time older cannabis consumers finds they weren’t looking for a high — they were looking for relief that medicine had stopped providing.

By Maya Torres | National | May 15, 2026

The 169 adults who sat for interviews with researchers from the University of Utah and the University of Colorado at Boulder weren’t young, and they weren’t casual experimenters. They were, on average, 60 years old or older, and they were trying cannabis for the first time.

Many of them had been trying other things for years.

A new study published in JAMA Network Open — one of the most widely read medical journals in the country — asked these first-time older consumers why they finally crossed the line from skeptic to user. The answers were consistent, and they tell a story that gets at something the pharmaceutical industry might not love to hear: millions of older Americans feel that medicine has let them down.

“A Last Resort”

The research team found that older adults weren’t picking up edibles or tinctures on a whim. They were people who had already run the gauntlet — prescription painkillers, sleep medications, anti-anxiety drugs — and come out the other side with either more problems than they’d started with, or no relief at all.

“Many participants described a reluctance in using traditional pharmaceutical treatments,” the study’s authors wrote. “Notably, they had concerns about adverse effects, long-term health risks, or dependency associated with pharmaceutical medications and viewed cannabis as a safer alternative.”

Some had tried physical therapy, acupuncture, and massage. Some had cycled through multiple drug regimens over years. By the time they turned to cannabis, researchers wrote, many described it plainly as “a last resort.”

The conditions driving them there were familiar: chronic pain — the kind that accumulates over decades of physical work, injury, or arthritis — and sleep disruption, which research consistently links to cognitive decline, depression, and cardiovascular risk in aging adults. Others cited anxiety and general quality-of-life concerns.

The Scale of the Shift

This study won’t come as a surprise to anyone tracking demographic trends in cannabis use. Survey data compiled by AARP shows roughly one in five older adults now says they’ve used cannabis products in the past year — a number that has climbed steadily since legalization expanded across the country.

But the JAMA study does something the trend data can’t: it puts names (well, anonymized voices) and reasons behind the numbers. These aren’t weekend warriors experimenting with edibles at a music festival. These are people in their 60s, 70s, and older who feel their doctors haven’t been able to help them, who worry about the addictive potential of the opioids they’ve been offered, and who have quietly decided to try something that — where legal — they can obtain without a prescription and without a co-pay.

That’s not a niche finding. That’s a window into a quiet, ongoing shift in how an entire generation is managing chronic illness.

What the Medical System Is Missing

There is a harder question beneath this data, and the study’s authors name it directly: older adults making this shift are largely doing it without guidance.

Most physicians still have limited training in cannabis pharmacology. In states where medical programs exist, doctors who certify patients often provide minimal counseling about dosing, drug interactions, or what to realistically expect. In states without medical programs, patients are navigating dispensary menus and online forums entirely on their own.

For a 68-year-old managing high blood pressure, diabetes, or a heart condition — all of which involve drug interactions that cannabis can complicate — that’s a genuine risk. Not because cannabis is uniquely dangerous in older adults, but because any substance taken without clinical oversight in a population managing multiple conditions carries unknowns.

The researchers called for “stronger clinical evidence, patient-centered guidance, and accessible education to help older adults confidently select edible cannabis products to address pain, sleep, or mental health concerns.” That’s measured, reasonable language for a journal article. In plain terms: the medical establishment hasn’t kept up with what patients are already doing.

An Equity Angle That Often Goes Unspoken

There’s a dimension to this story that tends to disappear in the data: not every older American has equal access to the safer end of this shift.

In states with legal markets, a senior with chronic pain can walk into a licensed dispensary, consult a trained budtender, and choose from tested, labeled products. In the 10 states that have not yet legalized any form of cannabis, that same senior is either going without, relying on black-market products with no quality control, or crossing state lines. The AARP number — one in five older adults using cannabis — almost certainly includes a significant population in prohibition states.

The public health implications of a two-tier system — where quality, safety, and access depend entirely on what state you happen to live in — are significant, and they fall hardest on older adults with limited mobility, fixed incomes, and the most complex medical needs.

What Comes Next

The study’s authors are careful about what their findings can and cannot claim. This was a qualitative interview study of 169 people — meaningful for understanding motivations, limited for drawing population-wide clinical conclusions. They’re calling for more research, not a policy overhaul.

But the trajectory is clear. Older Americans are already here. They are already using cannabis, in significant numbers, because conventional medicine hasn’t solved the problems they’re living with. The question isn’t whether that’s happening — the AARP numbers, the JAMA study, and years of state-level sales data confirm that it is. The question is whether the medical establishment, policymakers, and the cannabis industry itself will meet them with the information and access they need.

Or whether they’ll keep treating this as a fringe phenomenon while one in five seniors quietly figures it out alone.

Maya Torres covers national cannabis policy and the human stories behind the headlines for CannabisInquirer.com.